Negative Antiamyloid Drug Trial: Lessons Learned

Although crenezumab was not superior to placebo in individuals who are at high risk for Alzheimer's disease in the API ADAD Colombia Trial, results provide important data for future studies, experts say.
Medscape Medical News
Although crenezumab was not superior to placebo in individuals who are at high risk for Alzheimer’s disease in the API ADAD Colombia Trial, results provide important data for future studies, experts say.
Medscape Medical News